Friedrich-Miescher-Strasse 15
Tübingen 72076
Germany
49 7071 9883 0
http://www.curevac.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 500
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Franz-Werner Haas L.L.M., Ph.D., LL.M. | CEO, COO & Member of Exec. Board | N/A | N/A | 1970 |
Dr. Florian von der Mulbe M.B.A., Ph.D., MBA | Co-Founder, Member of Exec. Board, Chief Production Officer | N/A | N/A | 1973 |
Mr. Pierre Kemula B.Sc. | CFO & Member of Exec. Board | N/A | N/A | 1974 |
Ms. Mariola Fotin-Mleczek | CTO & Member of Exec. Board | N/A | N/A | 1967 |
Ms. Ulrike Gnad-Vogt | Chief Medical Officer & Member of Exec. Board | N/A | N/A | N/A |
Dr. Igor Splawski M.Sc., Ph.D. | Chief Scientific Officer | N/A | N/A | 1968 |
Mr. Matthew L. S. Beck | VP of Investor Relations | N/A | N/A | N/A |
Mr. Thorsten Schüller | Head of Corp. Communications | N/A | N/A | N/A |
Slavica Stevanovic-Heck | Head of HR | N/A | N/A | N/A |
Dr. Ingmar Hoerr | Co-Founder, CEO & Supervisory Board Chairman (Leave of Absence) | N/A | N/A | N/A |
CureVac N.V., a clinical-stage biopharmaceutical company, engages in developing various transformative medicines based on messenger ribonucleic acid (mRNA). Its lead proprietary programs include CV8102 that is in a Phase 1 dose escalating clinical trials for four types of cancers as a monotherapy and in combination with anti-PD-1; and CV7202, which is in a Phase 1 clinical trials as a vaccine candidate against rabies. It is also advancing mRNA vaccine program against coronavirus (SARS-CoV-2), which is in Phase 1 clinical trial. The company's partnered programs comprise BI1361849, a therapeutic vaccine candidate that is in a Phase 1/2 clinical trials to elicit antigen-specific immune responses against tumor-associated antigens frequently overexpressed in patients with non-small cell lung cancer; Cas9 mRNA constructs for use in gene editing therapeutics; mRNA based novel therapeutic antibodies; prophylactic vaccines to prevent picornaviruses, influenza, malaria, and rotavirus; and programs against SARS-CoV-2, Lassa virus, and yellow fever. It has strategic partnerships with Genmab, Arcturus, Acuitas, CRISPR Therapeutics, Boehringer Ingelheim, GlaxoSmithKline, the Bill & Melinda Gates Foundation, CEPI, Tesla Grohmann, and others. The company was founded in 2000 and is headquartered in Tübingen, Germany.
CureVac N.V.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.